Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,386,029
  • Shares Outstanding, K 39,387
  • Annual Sales, $ 53,020 K
  • Annual Income, $ -36,560 K
  • 60-Month Beta 1.44
  • Price/Sales 26.26
  • Price/Cash Flow N/A
  • Price/Book 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.96
  • Number of Estimates 3
  • High Estimate -0.79
  • Low Estimate -1.14
  • Prior Year 0.29
  • Growth Rate Est. (year over year) -431.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.67 +31.07%
on 10/15/19
36.89 -1.71%
on 11/05/19
+8.26 (+29.50%)
since 10/14/19
3-Month
23.73 +52.80%
on 08/15/19
36.89 -1.71%
on 11/05/19
+12.14 (+50.33%)
since 08/14/19
52-Week
10.72 +238.25%
on 12/24/18
36.89 -1.71%
on 11/05/19
+23.47 (+183.50%)
since 11/14/18

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ZYME with:

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 36.31
1st Resistance Point 35.75
Last Price 35.96
1st Support Level 34.62
2nd Support Level 34.05

See More

52-Week High 36.89
Last Price 35.96
Fibonacci 61.8% 26.89
Fibonacci 50% 23.81
Fibonacci 38.2% 20.72
52-Week Low 10.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar